Policy Notices

• Reminder: NIH Natural Disaster Policy Hurricanes Henri and Ida
  (NOT-OD-21-178)
  National Institutes of Health
  

General Notices

• NHLBI Announces Interest in Promoting Cardiovascular and Cardiometabolic Health in Early Stages of the Lifecourse: Pre-adolescence Through Adolescence to Young Adulthood
  (NOT-HL-21-020)
  National Heart, Lung, and Blood Institute
  

• The BRAIN Initiative Plan for Enhancing Diverse Perspectives (PEDP)
  (NOT-MH-21-310)
  National Institute of Mental Health
  National Center for Complementary and Integrative Health
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Neurological Disorders and Stroke
  

• Notice of Change to the Award Information in PAR-20-297 NIOSH Centers of Excellence for Total Worker Health (U19)
  (NOT-OH-21-011)
  National Institute for Occupational Safety and Health
  

• Notice of Change to Award Information for PAR-21-165
  (NOT-OH-21-012)
  National Institute for Occupational Safety and Health
  

• Receipt Date Added for Commercial Fishing Occupational Safety Training Project Grants (T03)
  (NOT-OH-21-013)
  National Institute for Occupational Safety and Health
  

• Receipt Date Added for Commercial Fishing Occupational Safety Research Cooperative Agreement (U01)
  (NOT-OH-21-014)
  National Institute for Occupational Safety and Health
  

• Request for Information (RFI) on User Experience with Scientific Data Sources and Tools
  (NOT-OD-21-182)
  Office of the Director, NIH
  

Notice of Changes to Funding Opportunities

• Notice to Extend the Expiration Date of PAR-18-877 "Early Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01 Clinical Trial Optional)"
  (NOT-AG-21-057)
  National Institute on Aging
  

• Notice to Extend the Expiration Date of PAR-18-878 "Late Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01 Clinical Trial Required)"
  (NOT-AG-21-058)
  National Institute on Aging
  

• Notice of Participation of the National Institute on Aging (NIA) in RFA-NS-21-014 "BRAIN Initiative: Targeted BRAIN Circuits Planning Projects TargetedBCPP (R34 Clinical Trials Not Allowed)"
  (NOT-AG-21-060)
  National Institute on Aging
  

• Notice of Participation of the National Institute of Allergy and Infectious Diseases (NIAID) in RFA-DA-22-031, HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R01 Clinical Trial Not Allowed)
  (NOT-AI-21-076)
  National Institute of Allergy and Infectious Diseases
  

• Notice of Participation of the National Institute of Allergy and Infectious Diseases (NIAID) in RFA-DA-22-032, HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R21 Clinical Trial Not Allowed)
  (NOT-AI-21-077)
  National Institute of Allergy and Infectious Diseases
  

• Notice of Change to the Expiration Date and the Last Receipt Date of PAR-19-287, "Research Projects in Cancer Systems Biology (U01 Clinical Trial Optional)"
  (NOT-CA-21-110)
  National Cancer Institute
  

• Notice of Change to NOT-EB-21-005 "NIBIB Guidance for Support of Clinical Trial Applications"
  (NOT-EB-21-020)
  National Institute of Biomedical Imaging and Bioengineering
  

• Notice of NHLBI Addition to PA-18-932: Increasing Uptake of Evidence-Based Screening in Diverse Adult Populations (R01 Clinical Trial Optional)
  (NOT-HL-21-027)
  National Heart, Lung, and Blood Institute
  

• Notice of Correction to Expiration Date for NOT-HL-21-024 Notice of Special Interest (NOSI): Bold New Bioengineering Research for Heart, Lung, Blood and Sleep Disorders and Diseases (Reissue)
  (NOT-HL-21-029)
  National Heart, Lung, and Blood Institute
  

• Notice to Extend PA-16-453 " AHRQ Conference Grant Programs (R13)"
  (NOT-HS-21-020)
  Agency for Healthcare Research and Quality
  

• Notice of Change to PAR-22-026 "Selectively Target Technology Development to Understand How Changes or Dysfunction at the Capillary, Arterioles, and Small Lymphatic Vessels Level Can Have Long-term Impact on AD/ADRD (R01 Clinical Trial Not Allowed)"
  (NOT-NS-22-018)
  National Institute of Neurological Disorders and Stroke
  

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity Announcement: Effectiveness and Implementation Research for Post-Acute Interventions to Optimize Long-Term Mental Health Outcomes in Low- and Middle-Income Countries (R34 Clinical Trial Optional)
  (NOT-MH-21-340)
  National Institute of Mental Health
  

Notices of Special Interest

• Notice of Special Interest (NOSI): Advancing Imaging, Device Production, and Clinical Capabilities in Digital Dentistry (R41/R42, R43/R44 Clinical Trial Not Allowed)
  (NOT-DE-21-012)
  National Institute of Dental and Craniofacial Research
  

• Notice of Special Interest (NOSI): Promoting Cardiovascular and Cardiometabolic Health in Early Stages of the Lifecourse: Pre-adolescence Through Adolescence to Young Adulthood
  (NOT-HL-21-015)
  National Heart, Lung, and Blood Institute
  

Funding Opportunities

• NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Independent Clinical Trial Not Allowed)
  (PAR-21-295)
  National Cancer Institute
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Clinical Trial Required)
  (PAR-21-296)
  National Cancer Institute
  Application Receipt Date(s): November 12, 2024
  
  

• Multipurpose Prevention Technology: Novel Systemic Options for Young Adults (R43/R44 Clinical Trial Not Allowed)
  (PAR-21-297)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Allergy and Infectious Diseases
  National Institute of Mental Health
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below:
  
  

• Multipurpose Prevention Technology: Novel Systemic Options for Young Adults (R41/R42 Clinical Trial Not Allowed)
  (PAR-21-298)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Mental Health
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s):
  
  

• NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
  (PAR-21-317)
  National Institute of Dental and Craniofacial Research
  Application Receipt Date(s): May 07, 2024
  
  

• NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed)
  (PAR-21-320)
  National Institute on Drug Abuse
  Application Receipt Date(s): November 15, 2021, March 15, 2022, August 10, 2022, November 15, 2022, March 15, 2023, August 10, 2023, November 15, 2023, March 15, 2024, August 9, 2024.
  
  

• Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)
  (PAR-21-322)
  National Cancer Institute
  Application Receipt Date(s): September 07, 2024
  
  

• Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)
  (PAR-21-323)
  National Cancer Institute
  Application Receipt Date(s): September 07, 2024
  
  

• Basic Research in Cancer Health Disparities (R03 Clinical Trial Not Allowed)
  (PAR-21-324)
  National Cancer Institute
  Application Receipt Date(s): September 07, 2024
  
  

• Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)
  (PAR-21-331)
  National Cancer Institute
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)
  (PAR-21-332)
  National Cancer Institute
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• NINDS Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)
  (PAR-22-022)
  National Institute of Neurological Disorders and Stroke
  National Institute on Aging
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
  
  

• Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)
  (PAR-22-027)
  National Institute on Drug Abuse
  Application Receipt Date(s): September 08, 2024
  
  

• Longitudinal Single Cell Characterization of ADRD Postmortem Tissue (R01 Clinical Trial Not Allowed)
  (PAR-22-029)
  National Institute of Neurological Disorders and Stroke
  National Institute on Aging
  Application Receipt Date(s): October 21, 2021
  
  

• Collaborative Partnership between Research Centers in Minority Institutions (RCMI) and Alcohol Research Centers (U54 Clinical Trial Optional)
  (RFA-AA-21-015)
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): December 15, 2021
  
  

• National Cancer Institute Youth Enjoy Science Research Education Program (R25 Clinical Trial Not Allowed)
  (RFA-CA-21-020)
  National Cancer Institute
  Application Receipt Date(s): October 28, 2021; September 28, 2022; September 28, 2023 No late applications will be accepted for this Funding Opportunity Announcement.
  
  

• Translational and Basic Science Research in Early Lesions (TBEL) (U54 Clinical Trial Not Allowed)
  (RFA-CA-21-054)
  National Cancer Institute
  Application Receipt Date(s): November 02, 2021
  
  

• Translational and Basic Science Research in Early Lesions (TBEL) Coordinating and Data Management Center (U24 Clinical Trial Not Allowed)
  (RFA-CA-21-055)
  National Cancer Institute
  Application Receipt Date(s): November 2, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials (CUSP2CT U01 Clinical Trial Not Allowed)
  (RFA-CA-21-057)
  National Cancer Institute
  Application Receipt Date(s): November 19, 2021
  
  

• Data, Evaluation and Coordinating Center for: A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials (CUSP2CT) (U24 Clinical Trial Not Allowed)
  (RFA-CA-21-058)
  National Cancer Institute
  Application Receipt Date(s): November 19, 2021
  
  

• National Program for the Career Development Of Physician Scientists in Diabetes Research (Diabetes - Docs) (K12 Clinical Trial Optional)
  (RFA-DK-21-019)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): November 18, 2021
  
  

• NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) Genetic Research Centers (GRCs) (U01 Clinical Trial Optional)
  (RFA-DK-21-022)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): December 21, 2021
  
  

• Pediatric Centers of Excellence in Nephrology (P50 Clinical Trial Optional)
  (RFA-DK-21-024)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): November 18, 2021
  
  

• Silvio O. Conte Digestive Diseases Research Core Centers (P30 Clinical Trial Optional)
  (RFA-DK-21-026)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Limited Competition for the Data Coordinating Center (DCC) for the NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) (U24 Clinical Trial Optional)
  (RFA-DK-21-502)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): December 21, 2021
  
  

• Limited Competition: Knockout Mouse Production and Phenotyping Project (UM1) Clinical Trial Not Allowed
  (RFA-HG-21-036)
  National Human Genome Research Institute
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Eye Institute
  National Heart, Lung, and Blood Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Environmental Health Sciences
  National Institute of Neurological Disorders and Stroke
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
  Office of Research on Women's Health
  Application Receipt Date(s): November 01, 2021
  
  

• Limited Competition: Knockout Mouse Phenotyping Project Data Coordination Center and Database (UM1 Clinical Trial Not Allowed)
  (RFA-HG-21-037)
  National Human Genome Research Institute
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Eye Institute
  National Heart, Lung, and Blood Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Environmental Health Sciences
  National Institute of Neurological Disorders and Stroke
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
  Office of Research on Women's Health
  Application Receipt Date(s): November 01, 2021
  
  

• HEAL Initiative: Interdisciplinary Teams to Elucidate the Mechanisms of Device-Based Pain Relief (RM1 Clinical Trial Optional)
  (RFA-NS-22-016)
  National Institute of Neurological Disorders and Stroke
  National Center for Advancing Translational Sciences
  National Center for Complementary and Integrative Health
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): November 03, 2021
  
  

• World Trade Center Health Research-Related to WTC Survivors (U01 no Applications with Responders Accepted)
  (RFA-OH-22-004)
  National Institute for Occupational Safety and Health
  Application Receipt Date(s): December 7, 2021; December 6, 2022; December 5, 2023; December 10, 2024 On-time submission requires that electronic applications be error-free and made available to CDC for processing from eRA Commons on or before the deadline date. Applications must be submitted to and validated successfully by Grants.gov/eRA Commons no later than 5:00 PM Eastern Time on the listed application due date. Applicant organizations are strongly encouraged to start the registration process at least 4 weeks prior to the application due date. Note: HHS/CDC grant submission procedures do not provide a period of time beyond the application due date to correct any error or warning notices of noncompliance with application instructions that are identified by Grants.gov or eRA systems (i.e., error correction window).